Epiomic Epidemiology Series: Asthma Forecast in 8 Major Markets 2016-2026

August 2016 | 60 pages | ID: EF4D4F8D29FEN
Black Swan Analysis limited

Abstracts

Asthma is a chronic disease involving airway inflammation, reversible airflow obstruction, and bronchial hyper-responsiveness. The condition is usually triggered by environmental factors of which the symptoms include: difficulty breathing, coughing, wheezing and in some cases a life-threatening asthma attack. Although the condition is not currently curable, the symptoms can be controlled to a more manageable state through stepping up and stepping down treatments according to disease progression.

This report provides the current prevalent population for Asthma across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Asthma have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The main co-morbidities associated with asthma include:

• Obesity
• Smoking
• COPD
• GERD
• Sleep disorders

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in the global Asthma market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Asthma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Asthma’s prevalent population.
• Identify sub-populations within Asthma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Asthma patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Cachexia
Features of Asthma Patients
  Asthma by Severity (GINA)
  Asthma by Phenotype (Haldar)
  Asthma by SARP Phenotype
Refractory (Severe Uncontrolled) Asthma
  Asthma by Atopic Sub-type
  Asthma by EOS + Sub-type
  Asthma by BMI Status
  Asthma by Smoking Status
Treatment of Asthma with Bronchodilators
Preventative treatment of Asthma
  Comorbidities in Asthma Patients
Healthcare Utilisation by patients with Asthma
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix
List of Figures
Clinical phenotypes of asthma using cluster analysis
Stepwise approach to treatment

List Of Tables

LIST OF TABLES

GINA Classification parameters
Prevalence of Asthma, total (000s)
Prevalence of Asthma, males (000s)
Prevalence of Asthma , females (000s)
Asthma patients by severity, total (000s)
Asthma patients by Phenotype (Haldar), total (000s)
Asthma patients by SARP Phenotype, total (000s)
Prevalence of Refractory (Severe Uncontrolled) Asthma, total (000s)
Asthma patients by Atopic sub-type, total (000s)
Asthma patients by EOS + sub-type, total (000s)
Asthma patients by BMI status, total (000s)
Asthma patients by smoking status, total (000s)
Treatment of asthma with quick-acting bronchodilators, total (000s)
Treatment of asthma with quick-acting bronchodilators by asthma severity (000s)
Patients with Asthma receiving preventative treatment, total (000s)
Patients receiving preventative treatment by asthma severity (000s)
Prevalence of GERD in Patients with Moderate & Severe Asthma, total (000s)
Prevalence of Diabetes in Patients with Moderate & Severe Asthma, total (000s)
Prevalence of COPD in asthma patients, total (000s)
Prevalence of Atopic Dermatitis in asthma patients, total (000s)
Hospitalised overnight due to asthma in past 12 months, total (000s)
Visited ER due to asthma in past 12 months, total (000s)
Unscheduled medical visit due to asthma in past 12 months, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Asthma by 5-yr age cohort, males (000s)
USA Prevalence of Asthma by 5-yr age cohort, females (000s)
France Prevalence of Asthma by 5-yr age cohort, males (000s)
France Prevalence of Asthma by 5-yr age cohort, females (000s)
Germany Prevalence of Asthma by 5-yr age cohort, males (000s)
Germany Prevalence of Asthma by 5-yr age cohort, females (000s)
Italy Prevalence of Asthma by 5-yr age cohort, males (000s)
Italy Prevalence of Asthma by 5-yr age cohort, females (000s)
Spain Prevalence of Asthma by 5-yr age cohort, males (000s)
Spain Prevalence of Asthma by 5-yr age cohort, females (000s)
United Kingdom Prevalence of Asthma by 5-yr age cohort, males (000s)
United Kingdom Prevalence of Asthma by 5-yr age cohort, females (000s)
Brazil Prevalence of Asthma by 5-yr age cohort, males (000s)
Brazil Prevalence of Asthma by 5-yr age cohort, females (000s)
Japan Prevalence of Asthma by 5-yr age cohort, males (000s)
Japan Prevalence of Asthma by 5-yr age cohort, females (000s)